@IndexInvestor Thank you for correcting on the royalties part.
I am a bit confused regarding P3 trials. Isn't the point of partnership milestones to cover the cost of future (i.e. P3) trials? If so, we would not have much (if any) P3 readouts at the time of forming a partnership. Or am I missing something?
It is worth noting that a a P3 drug is significantly de-risked compared to a P2 asset. P2 readouts would not weight as much as P3 readout when negotiating a partnership.
General Comments / Chat, page-2686
-
- There are more pages in this discussion • 8,565 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.040(2.93%) |
Mkt cap ! $239.3M | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.50 | $1.35 | $167.2K | 118.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3547 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 2072 | 1 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |